Insulin Lispro (Humalog)

Insulin that has been modified so that the B-chain contains a LYSINE at position 28 instead of a PROLINE and a PROLINE at position 29 instead of a LYSINE. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.

Also Known As:

Networked: 565 relevant articles (70 outcomes, 177 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Liu, Rong: 11 articles (01/2022 - 02/2014)
2.	Heise, Tim: 9 articles (01/2022 - 09/2016)
3.	Milicevic, Zvonko: 9 articles (10/2016 - 01/2002)
4.	Dellva, Mary Anne: 8 articles (01/2022 - 10/2020)
5.	Fahrbach, Jessie L: 8 articles (05/2015 - 05/2009)
6.	Garg, Satish K: 7 articles (01/2022 - 05/2003)
7.	Jiang, Honghua: 7 articles (10/2016 - 01/2008)
8.	Hardy, Thomas: 6 articles (01/2022 - 11/2020)
9.	Leohr, Jennifer: 6 articles (01/2022 - 10/2020)
10.	Bode, Bruce: 6 articles (12/2021 - 03/2002)

Related Diseases

1.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 11/01/2018 - "To investigate the safety and efficacy of BioChaperone Lispo (BCLIS), an ultra-rapid formulation of insulin lispro (LIS) in people with type 1 diabetes. " 05/01/1999 - "Long-term efficacy of humalog in subjects with Type 1 diabetes mellitus." 01/01/2023 - "To evaluate the efficacy and safety of ultra-rapid lispro (URLi) versus lispro in a paediatric population with type 1 diabetes (T1D) in a Phase 3, treat-to-target study. " 01/01/2023 - "Efficacy and safety of ultra-rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO-Peds trial." 09/01/2021 - "The PRONTO-T1D study evaluated the efficacy and safety of ultra rapid lispro (URLi) versus lispro in adults with type 1 diabetes mellitus. "
2.	Type 2 Diabetes Mellitus (MODY) 08/01/2022 - "Efficacy and Safety of Ultra-Rapid Lispro in Younger and Older Patients with Type 2 Diabetes: Randomized Double-Blind PRONTO-T2D Study." 12/01/2020 - "This study compared the insulin lispro pharmacokinetics and glucodynamics, safety and tolerability of URLi and Humalog® after a single subcutaneous dose in patients with type 2 diabetes mellitus (T2DM). " 09/01/2020 - "The aim of this study was to evaluate the efficacy and safety of ultra-rapid lispro (URLi) versus lispro in a subgroup analysis of Japanese adults with type 2 diabetes mellitus (T2DM) from the phase 3 PRONTO-T2D trial. " 05/01/2018 - "A randomized, open-label, comparative, crossover trial on preference, efficacy, and safety profiles of lispro insulin u-100 versus concentrated lispro insulin u-200 in patients with type 2 diabetes mellitus: a possible contribution to greater treatment adherence." 12/01/2014 - "Response to comment on Edelman et al. AUTONOMY: the first randomized trial comparing two patient-driven approaches to initiate and titrate prandial insulin lispro in type 2 diabetes. "
3.	Hypoglycemia (Reactive Hypoglycemia) 08/01/2022 - "URLi, in a basal-bolus regimen, resulted in endpoint HbA1c < 7% and significantly lower PPG excursions compared to lispro in both age groups, with reduced level 2 hypoglycemia in older versus younger patients. " 08/01/2022 - "The relative rate (URLi/Humalog) of level 2 hypoglycemia was lower in older versus younger patients, with a significant treatment-by-age interaction observed. " 08/01/2022 - "In this sub-group analysis, we compared URLi to lispro on the change from baseline  in HbA1c and rate of level 2 hypoglycemia (< 54 mg/dl) in patients aged < 65 (N = 406) and ≥ 65 years (N = 267). " 09/01/2021 - "There were no significant treatment differences in the incidences of treatment-emergent adverse events, documented hypoglycemia and severe hypoglycemia; however, the rate of documented hypoglycemia was lower in the mealtime URLi arm compared with the lispro arm. " 11/01/2020 - "Mealtime URLi increased daytime time in range (71-180 mg/dL [3.9-10.0 mmo/L]) (LSM difference = +43.6 min, P = 0.020) and decreased nighttime time in hypoglycemia (LSM difference ≤70 mg/dL [3.9 mmol/L] = -11.5 min, P = 0.009) compared to mealtime lispro. "
4.	Diabetes Mellitus 01/01/1998 - "Safety and efficacy of insulin lispro in patients with diabetes mellitus." 01/01/1997 - "We examined the safety and efficacy of insulin lispro in the premeal treatment of patients with diabetes mellitus. " 09/01/2020 - "We evaluated the efficacy and safety of ultra-rapid lispro (URLi) in comparison to lispro in a subgroup analysis of Japanese adults with type 1 diabetes mellitus from the phase 3 PRONTO-T1D trial. " 05/01/2020 - "This study compared the pharmacokinetic and glucodynamic profiles, safety, and tolerability of URLi and lispro (Humalog® ) in Japanese patients with type 1 diabetes mellitus. " 11/01/1996 - "A few of the studies used patients with diabetes mellitus in multicenter, randomized, crossover trials of insulin lispro. "
5.	Hyperglycemia 03/01/2008 - "These findings suggest that insulin lispro could be useful for the treatment of hyperglycemia in type 1 diabetic pregnant women." 01/01/2022 - "The rate of EIS failure due to unexplained hyperglycemia at the end of day 7 was 0.1% (95% confidence interval [CI]: 0.03-0.51) and 0.4% (95% CI: 0.16-1.00) for insulin lispro and aspart use, respectively. " 06/30/2015 - "In the type 2 diabetic patient, "rebound hyperglycemia" occurred after SQ lispro was rapidly metabolized. " 09/07/2014 - "With continuous enteral feeds and borderline to mild IR, Lispro showed minimal effect on GV; however, rebound hyperglycemia that increased GV occurred when the IR was moderate to high. " 03/01/1997 - "We hypothesize that this lack of improvement is attributable to the development of late postprandial hyperglycemia secondary to a waning of Lispro insulin's effect in conjunction with continued meal absorption. "

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Insulin Aspart (NovoLog)
3.	Glucose (Dextrose)
4.	Insulin Glargine (Lantus)
5.	Hypoglycemic Agents (Hypoglycemics)
6.	Protamines (Protamine Sulfate)
7.	Short-Acting Insulin
8.	Insulin Lispro (Humalog)
9.	Insulins
10.	Isophane Insulin (NPH Insulin)

Related Therapies and Procedures

1.	Glycemic Control
2.	Therapeutics
3.	Injections
4.	Subcutaneous Infusions
5.	Subcutaneous Injections